Blood Tests Tracking Prostate Cancer During PSMA Radioligand Therapy
Studies blood samples in men with advanced prostate cancer receiving PSMA radioligand therapy.
Plain-language title generated from the registry record
Registry title: Liquid Biopsy Under PSMA Radioligand Therapy
Key facts
- Where
- Augsburg, München, and Würzburg, GermanySee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with metastatic castration-resistant prostate cancer who are going to get PSMA radioligand therapy as approved. Blood samples will be studied before, during and after the treatment.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic castration-resistant prostate cancer (mCRPC) that can be treated with PSMA radioligand therapy
- Earlier treatment
- One earlier line of antiandrogen receptor pathway treatment and one earlier line of taxane-based therapy
- Biomarker or test result
- A PSMA PET/CT scan done no more than 8 weeks before the first cycle of PSMA radioligand therapy
Main reasons for not taking part
- Unwilling to follow the study procedures
- No advice for PSMA radioligand therapy from the interdisciplinary tumor conference
Read by machine on 12 November 2026.
Where in Germany
- University hospital Wuerzburg - Department of Nuclear MedicineAugsburg, GermanyContact: Constantin Lapa, Prof.Taking people
- TUM Klinikum rechts der Isar - Department of Nuclear medicineMünchen, GermanyContact: Matthias Eiber, Prof.Taking people
- University hospital Wuerzburg - Department of Nuclear MedicineWürzburg, GermanyContact: Kerstin Michalski, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Wuerzburg University Hospital
- Trial code
- NCT07118436
- Record updated
- 12 August 2025
- Original description
Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patients with metastatic castration-resistant prostate cancer (mCRPC) can be offered radioligand therapy (RLT) that targets the prostate-specific membrane antigen (PSMA). Despite an initially high response rate to PSMA-RLT, the disease often progresses rapidly again. The underlying mechanisms are still poorly understood.Read full original descriptionShow less
Liquid Biopsy as a Biomarker in Patients Treated With PSMA Radioligand Therapy
Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patients with metastatic castration-resistant prostate cancer (mCRPC) can be offered radioligand therapy (RLT) that targets the prostate-specific membrane antigen (PSMA). Despite an initially high response rate to PSMA-RLT, the disease often progresses rapidly again. The underlying mechanisms are still poorly understood.
Liquid biopsy (LBx) involves the collection and analysis of body fluids, particularly blood. Its major advantage compared to a tissue sample is its non-invasive nature, allowing for multiple samplings, as well as the examination of more than just a single punctured lesion. Among other things, circulating tumor DNA (ctDNA) can be detected in the blood.
The aim of this study is to apply LBx before, during, and after PSMA-RLT in patients with mCRPC to determine prognostic factors before therapy and to assess the value of LBx in evaluating treatment response. Furthermore, LBx will be used to gather information on the course of potential tumor heterogeneities and to determine resistance mechanisms against PSMA-RLT.
To this end, patients receiving PSMA-RLT will be enrolled in the study at three sites (University Hospital Wuerzburg, University Hospital Augsburg, Klinikum rechts der Isar Munich). The evaluation of clinical and imaging parameters will be carried out centrally at the University Hospital Wuerzburg, while the analysis of LBx will be performed at the University Hospital Augsburg.
Inclusion: Patients with mCRPC eligble for PSMA RLT; In-lable use for PSMA RLT; PSMA PET/CT not older than 8 weeks prior to first cycle of PSMA RLT; One previous line of antiandrogen receptor pathway treatment and one previous line of taxan based therapy; Age ≥ 18 years; Written informed consent; Sufficient knowledge of the German language or presence of a translator.
Exclusion: Unwilling to adhere to study procedures; Missing interdisciplinary tumor conference advise for PSMA RLT.